+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H1 2020

  • ID: 5128973
  • Drug Pipelines
  • June 2020
  • Region: Global
  • 37 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bavarian Nordic A/S
  • IDBiologics Inc
  • Sigmovir Biosystems Inc
  • Visterra Inc
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H1 2020

Summary

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Respiratory syncytial virus G protein is a protein produced by respiratory syncytial virus. It attaches the virion to the host cell membrane by interacting with heparan sulfate. It interacts with host CX3CR1, the receptor for the CX3C chemokine fractalkine, to modulate the immune response and facilitate infection. Secreted glycoprotein G helps RSV escape antibody-dependent restriction of replication by acting as an antigen decoy and by modulating the activity of leukocytes bearing Fc gamma receptors.

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) pipeline Target constitutes close to 6 molecules. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 4 and 1 respectively. Report covers products from therapy areas Infectious Disease which include indications Respiratory Syncytial Virus (RSV) Infections.

The latest report Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H1 2020, outlays comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G)
  • The report reviews Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bavarian Nordic A/S
  • IDBiologics Inc
  • Sigmovir Biosystems Inc
  • Visterra Inc
  • MORE
  • Introduction
  • Report Coverage
  • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Overview
  • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Companies Involved in Therapeutics Development
  • AstraZeneca Plc
  • Bavarian Nordic A/S
  • Beijing Advaccine Biotechnology Company Ltd
  • IDBiologics Inc
  • Sigmovir Biosystems Inc
  • Visterra Inc
  • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Drug Profiles
  • Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • respiratory syncytial virus (virus like particle) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • respiratory syncytial virus vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • respiratory syncytial virus vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TRL-3D3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VIS-RSV - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Dormant Products
  • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Product Development Milestones
  • Featured News & Press Releases
  • Aug 08, 2018: Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine
  • Mar 06, 2018: Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine
  • Nov 09, 2017: Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine
  • Sep 21, 2017: Bavarian Nordic Provides Update on its Universal RSV Vaccine
  • Jun 27, 2017: Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine
  • Feb 23, 2017: Updated Phase 1 Data Show Bavarian Nordic's Vaccine Candidate Induces a Broad and Durable Immune Response against RSV
  • Dec 14, 2016: Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine
  • Oct 18, 2016: Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine
  • Sep 29, 2016: Bavarian Nordic Announces Presentation Of Phase 1 Data For Its RSV Vaccine At International RSV Symposium
  • May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations
  • Aug 18, 2015: Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN in Respiratory Syncitial Virus
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by AstraZeneca Plc, H1 2020
  • Pipeline by Bavarian Nordic A/S, H1 2020
  • Pipeline by Beijing Advaccine Biotechnology Company Ltd, H1 2020
  • Pipeline by IDBiologics Inc, H1 2020
  • Pipeline by Sigmovir Biosystems Inc, H1 2020
  • Pipeline by Visterra Inc, H1 2020
  • Dormant Projects, H1 2020
List of Figures
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
  • AstraZeneca Plc
  • Bavarian Nordic A/S
  • Beijing Advaccine Biotechnology Company Ltd
  • IDBiologics Inc
  • Sigmovir Biosystems Inc
  • Visterra Inc
Note: Product cover images may vary from those shown
Adroll
adroll